GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
1-Year Est. Return
70.11%
This Fund
S&P 500
1 Year Est. Return
+70.11%
AUM
$276M
AUM Growth
-$11.6M
(-4%)
Holding
70
Top Buys
| 1 | +$14.7M | |
| 2 | +$9.93M | |
| 3 | +$8.99M | |
| 4 |
Janux Therapeutics
JANX
|
+$6.09M |
| 5 |
Dyne Therapeutics
DYN
|
+$3.98M |
Top Sells
| 1 | +$19.1M | |
| 2 | +$8.38M | |
| 3 | +$8.04M | |
| 4 |
Soleno Therapeutics
SLNO
|
+$7.18M |
| 5 |
Vaxcyte
PCVX
|
+$6.31M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Sarepta Therapeutics
SRPT
$1.76B
| $15M | 5.43% |
120,000
+65,000
|
|
||
2
Novo Nordisk
NVO
$166B
| $13.1M | 4.75% |
+110,000
|
|
||
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $12.9M | 4.7% |
140,000
+100,000
|
|
||
4
Axsome Therapeutics
AXSM
$8.38B
| $12.1M | 4.4% |
135,000
-15,000
|
|
||
5
Tarsus Pharmaceuticals
TARS
$3.21B
| $11.5M | 4.17% |
350,000
+115,000
|
|
||
6
Perspective Therapeutics
CATX
$615M
| $10M | 3.63% |
750,000
-175,000
|
|
||
7
CG Oncology
CGON
$4.86B
| $9.43M | 3.42% |
250,000
-10,000
|
|
||
8
Roivant Sciences
ROIV
$20.7B
| $9.23M | 3.35% |
800,000
-200,000
|
|
||
|
9
Vaxcyte
PCVX
$8.86B
| $9.14M | 3.31% |
80,000
-70,000
|
|
||
10
Viking Therapeutics
VKTX
$3.91B
| $8.86M | 3.21% |
140,000
+45,000
|
|
||
11
Syndax Pharmaceuticals
SNDX
$1.89B
| $8.66M | 3.14% |
450,000
+100,000
|
|
||
|
12
Janux Therapeutics
JANX
$819M
| $8.63M | 3.13% |
190,000
+140,000
|
|
||
13
Ascendis Pharma
ASND
$14.3B
| $7.84M | 2.84% |
52,500
-34,221
|
|
||
14
Crinetics Pharmaceuticals
CRNX
$4.21B
| $7.67M | 2.78% |
150,000
-90,000
|
|
||
|
15
Soleno Therapeutics
SLNO
$2.1B
| $7.57M | 2.75% |
150,000
-150,000
|
|
||
16
TG Therapeutics
TGTX
$4.78B
| $7.25M | 2.63% |
310,000
-190,000
|
|
||
17
Rezolute
RZLT
$307M
| $7.15M | 2.59% |
1,474,995
+53,494
|
|
||
18
Phathom Pharmaceuticals
PHAT
$980M
| $6.78M | 2.46% |
375,000
-225,000
|
|
||
19
MoonLake Immunotherapeutics
MLTX
$1.24B
| $6.47M | 2.35% |
128,411
-171,589
|
|
||
20
Olema Pharmaceuticals
OLMA
$1.94B
| $6.39M | 2.32% |
535,000
-15,000
|
|
||
21
Immunovant
IMVT
$5.64B
| $6.13M | 2.22% |
215,000
-45,000
|
|
||
22
Insmed
INSM
$31.8B
| $5.47M | 1.99% |
75,000
+10,000
|
|
||
23
Edgewise Therapeutics
EWTX
$3.22B
| $5.2M | 1.89% |
+195,000
|
|
||
24
Replimune Group
REPL
$632M
| $4.93M | 1.79% |
450,000
|
|
||
25
BridgeBio Pharma
BBIO
$12.9B
| $4.46M | 1.62% |
175,000
+35,000
|
|